重组改构人肿瘤坏死因子治疗晚期肺癌癌性胸腔积液疗效的影响因素分析

魏东; 汤礼军; 张伶; 谭燕; 高辉

您当前的位置：

首页 >

文章列表页 >

重组改构人肿瘤坏死因子治疗晚期肺癌癌性胸腔积液疗效的影响因素分析

临床研究 | 更新时间：2024-01-17

- 重组改构人肿瘤坏死因子治疗晚期肺癌癌性胸腔积液疗效的影响因素分析
- Factors affecting the efficacy of rmhTNF for advanced lung cancer with maglignant pleural effusion
- 重庆医科大学学报 2009年34卷第4期页码：472-475
- 作者机构：
  
  四川成都军区总医院肿瘤中心
- 作者简介：
- 基金信息：
- DOI：
  中图分类号： R734.2
- 纸质出版日期：2009，
扫描看全文
[1]魏东,汤礼军,张伶,谭燕,高辉.重组改构人肿瘤坏死因子治疗晚期肺癌癌性胸腔积液疗效的影响因素分析[J].重庆医科大学学报,2009,34(04):472-475.

WEI Dong, et al. Factors affecting the efficacy of rmhTNF for advanced lung cancer with maglignant pleural effusion[J]. Journal of Chongqing Medical University, 2009,34(4):472-475.
[1]魏东,汤礼军,张伶,谭燕,高辉.重组改构人肿瘤坏死因子治疗晚期肺癌癌性胸腔积液疗效的影响因素分析[J].重庆医科大学学报,2009,34(04):472-475. DOI：

WEI Dong, et al. Factors affecting the efficacy of rmhTNF for advanced lung cancer with maglignant pleural effusion[J]. Journal of Chongqing Medical University, 2009,34(4):472-475. DOI：

摘要

目的:分析影响重组改构人肿瘤坏死因子（Recombinant mutant human tumor necrosis factor

rmhTNF）治疗晚期肺癌癌性胸腔积液疗效的因素。方法:回顾性分析我科应用rmhTNF治疗晚期肺癌癌性胸腔积液198例病人的临床资料

分析年龄、性别、病理类别、胸水部位、胸水量、肿瘤远处转移、KPS评分、治疗药物剂量（小剂量rmhTNF500万IU组、大剂量rmhTNF1500万IU组）、全身化疗等因素对肺癌癌性胸水疗效的影响

对有意义的因素进一步采用非条件Logistic回归分析。结果:198名患者中CR53例

PR95例

总有效率为74.7%。单因素分析显示年龄、胸水部位、胸水量、KPS评分、治疗药物剂量、辅助化疗等对肺癌胸水的疗效有影响;多因素分析显示治疗药物剂量、KPS评分、胸水量与疗效有关。结论:治疗药物剂量、KPS评分、胸水量是rmhTNF治疗肺癌恶性胸腔积液的独立的影响因素。大剂量rmhTNF1500万IU、KPS评分>60

胸水量少的患者疗效好。

Abstract

Objective:To investigate the factors affecting the curative effect of recombinant mutant human tumor necrosis factor(rmhTNF) on patients with malignant pleural effusion caused by advanced lung cancer.Methods:The data of 198 patients were reviewed.Patients were assigned into two groups.One was treated with 5 million IU(low dose)

another with 15 million IU rmhTNF(high dose).The clinical efficacy of rmhTNF was analyzed with test and the prognostic factors of patients were calculated by multivariate unconditional logistic regression analysis.Results:In 198 patients treated with rmhTNF

the number of patients with complete response(CR)was 53

the number of patients with partial response(PR)was 95

the response rate being 74.7%.Age and Karnofsky Performance Score(KPS)of patients

location and quantity of malignant pleural effusion

dose of rmhTNF and neoadjuvant chemotherapy were associated with the clinical efficacy of rmhTNF.Dose of rmhTNF

KPS and quantity of malignant pleural effusion were selected as prognostic factors in the multivariate analysis.Conclusion:In treating malignant pleural effusion caused by advanced lung cancer

dose of rmhTNF

KPS and quantity of pleural effusion are independent prognostic factors.The patients(KPS>60

treated with high dose rmhTNF and low quantity of pleural effusion)present fine clinical effect.

关键词

肺癌恶性胸腔积液重组改构人肿瘤坏死因子

Keywords

LungcancerMalignant pleural effusionRecombinant mutant human tumor necrosis factor(rmhTNF)

references

浏览量

161

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据